Skip to main navigation

Search for:

Search

Rubius Therapeutics

About Us
Our Science
Our Pipeline
Investors & Media
Contact

Menu Search

Press Releases

Year

May 24, 2022

Rubius Therapeutics Appoints Noubar Afeyan as Chairman of its Board of Directors

May 10, 2022

Rubius Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update

April 26, 2022

Rubius Therapeutics to Announce First Quarter 2022 Financial Results

April 8, 2022

Rubius Therapeutics Reports Updated Clinical Data at AACR from the Ongoing Monotherapy Phase 1 Arm of the Phase 1/2 Clinical Trial of RTX-240 in Advanced Solid Tumors Demonstrating Single-Agent Activity and Favorable Tolerability

April 7, 2022

Rubius Therapeutics to Host Investor Webcast to Discuss Updated Clinical Data at AACR from the Ongoing Monotherapy Phase 1 Arm of the Phase 1/2 Clinical Trial of RTX-240 in Patients with Advanced Solid Tumors on April 8, 2022, at 1:15 PM ET

March 8, 2022

Rubius Therapeutics to Present Updated Results from Single-Agent Phase 1 Clinical Trial of RTX-240 at the American Association of Cancer Research Annual Meeting

February 25, 2022

Rubius Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

February 14, 2022

Rubius Therapeutics to Announce Fourth Quarter and Full Year 2021 Financial Results

February 1, 2022

Rubius Therapeutics to Present at the Virtual Guggenheim Healthcare Talks and SVB Leerink Global Healthcare Conference in February 2022

January 13, 2022

Rubius Therapeutics Announces Dosing of First Patient in Phase 1/2 Trial of RTX-224, a Broad Immune Agonist, for the Treatment of Certain Solid Tumors

Pagination

First page
Previous page
Page 1
Current page 2
Page 3
Next page
Last page

Displaying 11 - 20 of 22

Print Page

RSS Feeds

Share Page

Email Alerts

Contact Us

399 Binney St, Suite 300
Cambridge, MA 02139 617-679-9600

Share

LinkedIn Twitter YouTube FaceBook

Home
About Us
Our Science
Our Pipeline
Investors
Careers
Sitemap
Terms of Use
Privacy Policy

© Rubius Therapeutics, Inc. 2023. All Rights Reserved. RUBIUS and RED PLATFORM are registered trademarks of Rubius Therapeutics, Inc. RUBIUS THERAPEUTICS, RED CELL THERAPEUTICS and RCT are trademarks of Rubius Therapeutics, Inc. All other trademarks referenced herein are the properties of their respective owners.

Facebook
Twitter
LinkedIn